戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 designed to neutralize IL-5 (mepolizumab and reslizumab).
2 esis of asthma (eg, omalizumab, mepolizumab, reslizumab).
3 d trial of the humanized anti-IL-5 antibody, reslizumab, (1.0 mg/kg IV) administered 3 to 7 days prio
4 d trial of the humanized anti-IL-5 antibody, reslizumab, (1.0 mg/kg IV) administered 3 to 7 days prio
5 assigned (1:1) to receive either intravenous reslizumab (3.0 mg/kg) or placebo every 4 weeks for 1 ye
6 izumab 432 (17.3%), dupilumab 13 (0.5%), and reslizumab 5 (0.2%).
7          We sought to evaluate the effect of reslizumab, a neutralizing antibody against IL-5, in chi
8 , 67%, 64%, and 24% in the 1, 2, and 3 mg/kg reslizumab (all P < .001) and placebo groups, respective
9 ralizing monoclonal antibodies (mepolizumab, reslizumab and benralizumab) are currently available for
10 f DEC treatment in all subjects who received reslizumab and in none of the placebo subjects.
11 sessment scores; the differences between the reslizumab and placebo groups were not statistically sig
12 thways (IL-5R and IL-5), namely mepolizumab, reslizumab, and benralizumab, are effective and safe for
13                Three biologics, mepolizumab, reslizumab, and benralizumab, inhibit the IL-5 or IL-5 r
14                              Safety data for reslizumab, another anti-IL-5 monoclonal antibody, and b
15 dy 1; 119 [51%] for placebo and 67 [29%] for reslizumab for study 2), upper respiratory tract infecti
16                          One patient in each reslizumab group and 2 in the placebo group had serious
17                          Two patients in the reslizumab group had anaphylactic reactions; both respon
18        The most common adverse events in the reslizumab groups were headache, cough, nasal congestion
19          In both studies, patients receiving reslizumab had a significant reduction in the frequency
20             These results support the use of reslizumab in patients with asthma and elevated blood eo
21 e aimed to assess the efficacy and safety of reslizumab in patients with inadequately controlled, mod
22 toms (127 [52%] for placebo and 97 [40%] for reslizumab in study 1; 119 [51%] for placebo and 67 [29%
23                                              Reslizumab is a humanised anti-interleukin 5 monoclonal
24                                              Reslizumab is a humanized anti-IL-5 monoclonal antibody
25                                  Single dose reslizumab lowered the AEC by 77% prior to initiation of
26 953 were randomly assigned to receive either reslizumab (n=477 [245 in study 1 and 232 in study 2]) o
27 nt received a specific volume of study drug (reslizumab or matching placebo) on the basis of the pati
28 ned to receive infusions of 1, 2, or 3 mg/kg reslizumab or placebo at weeks 0, 4, 8, and 12.
29 numab" or "Nemolizumab" or "Mepolizumab" or "Reslizumab" or "Benralizumab".
30 7, -4.97) with benralizumab, mepolizumab and reslizumab, respectively.
31                                              Reslizumab significantly reduced intraepithelial esophag
32    The monoclonal antibodies mepolizumab and reslizumab target the ligand IL-5, preventing its intera
33  of treatment of the response to intravenous reslizumab treatment at 52 weeks, but it was not suitabl
34                         In summary, although reslizumab was able to blunt peripheral eosinophilia pos
35                     Common adverse events on reslizumab were similar to placebo.
36  New anti-IL-5 therapeutics, mepolizumab and reslizumab, were US Food and Drug Administration approve